Independent research context
Guides, comparisons, and research summaries for following ibogaine clinical trial news and pipeline updates with care for evidence, uncertainty, and safety context.
A practical orientation
Still Threshold 82 is an independent resource for patients, families, researchers, policymakers, and others seeking clear context on ibogaine and noribogaine clinical development. The main research overview provides a starting point for understanding how trial progress, regulation, safety questions, and development claims fit together.
These offerings are informational: they help separate investigational research from unverified treatment claims. Our approach and editorial principles explain why the resource emphasizes primary records, plain language, and clear limits on what current evidence can establish.
The working set
Concise summaries track stated study aims, development stage, sponsor disclosures, and the limits of early findings. They are designed to make clinical trial updates easier to place in context without turning preliminary work into a promise.
Guides surface useful distinctions: a registered study is not a result, a result is not a broadly established treatment, and an investigational compound is not a routine clinical service. For definitions that anchor those distinctions, consult plain-language ibogaine terminology.
Comparison notes distinguish ibogaine-related compounds, clinical pathways, stated research objectives, and the practical questions surrounding duration. A focused overview of how long ibogaine effects may last can help readers identify why time course is not the same as safety or efficacy.
Safety material keeps contraindications, monitoring, interactions, and uncertainty visible alongside development updates. Information about supervised ibogaine settings is framed as context for evaluating claims, not as a recommendation or referral.
Maker’s bench
A useful update begins with the record: what intervention is being studied, for which stated purpose, in what phase, and with what publicly described design. ClinicalTrials.gov is maintained by the U.S. National Library of Medicine and is one place where registered study records can be checked against wider claims.
Pipeline language can also obscure important differences between substances, formulations, and research programs. Resources discussing ibogaine hydrochloride context can help readers recognize a term before assuming that a product label answers questions about evidence, oversight, or risk.
“The work is to make the source, status, and uncertainty legible—not to turn sparse information into certainty.” Still Threshold 82
Provenance proof
Common questions
No. Still Threshold 82 is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its material is not medical or legal advice and does not replace individualized professional care.
Updates are organized around stated study status, design, regulatory context, and limitations. When readers encounter early-stage programs such as ibogaine pilot research, the central question is what the study can actually support, rather than what an announcement may imply.
Because research interest does not remove risk or establish approval. The U.S. Food and Drug Administration explains that drug development and approval involve a structured process; the presence of a research program should be read within that broader framework.
Use the trial tracker, regulatory timeline, and safety material as a connected set of context—not as a substitute for medical, legal, or regulatory advice.